Platelet Bioenergetics in TBI

Sponsor
Kevin Hatton (Other)
Overall Status
Terminated
CT.gov ID
NCT04271059
Collaborator
(none)
1
1

Study Details

Study Description

Brief Summary

This is a prospective study enrolling 5 patients with a diagnosis of traumatic brain injury (TBI) without polytrauma and 5 patients with TBI with polytrauma admitted to the University of Kentucky (UK) Chandler Medical Center to evaluate differences in platelet bioenergetics in the populations. Additionally, five healthy subjects will be recruited to the control group.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Traumatic brain injury (TBI) is used to describe a myriad of primary and secondary brain-related injuries related to trauma. Clinically, moderate-to-severe brain injury results in early coagulopathy, with a tendency toward unanticipated bleeding, followed by delayed hypercoagulation, with a tendency toward unanticipated clot formation. Optimal platelet count, activation and function are necessary for normal coagulation. Investigators have recently developed a novel approach to measure platelet activity. This approach specifically measures platelet energy output or bioenergetics from blood samples. Preclinical (animal) studies show that platelet bioenergetic profiles are different after TBI and that they change over time. This temporal profile may be used as a biomarker that can inform diagnosis and prognosis of TBI.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    The Effect of Platelet Bioenergetics in Traumatic Brain Injuries
    Actual Study Start Date :
    Feb 13, 2020
    Actual Primary Completion Date :
    Feb 13, 2020
    Actual Study Completion Date :
    Feb 13, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    TBI without polytrauma

    Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) within the last 12 hours, without additional polytrauma.

    TBI with polytrauma

    Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) and polytrauma, including major trauma to the chest, abdomen, pelvis or extremities. within the last 12 hours.

    Healthy Control

    Subjects who have not experienced any TBIs within the last six months.

    Outcome Measures

    Primary Outcome Measures

    1. Change in Platelet Bioenergetics [0-72 hours]

      Change in various platelet oxygen consumption rates and extracellular acidification rate

    Secondary Outcome Measures

    1. Identify platelet bioenergetic rate of healthy adults. [24 hour.]

      Identify normal platelet oxygen consumption rates and extracellular acidification rate based on patient demographics.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients must have moderate to severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) to be enrolled in the TBI or TBI with trauma groups.

    • Patients enrolled in the TBI with polytrauma group must also exhibit polytrauma including concomitant traumatic brain injury, major trauma to the chest, abdomen, pelvis or extremities.

    • Patients must be greater than or equal to 18 years of age and must be less than or equal to 50 years of age.

    • Patients must be able to cooperate for a detailed neurologic exam.

    • Patients must be consented and undergo first blood sampling within the first 12 hours (+/- 2 hours) after their traumatic brain injury to be enrolled in the TBI or TBI with trauma groups.

    • Patients must be expected to survive to discharge, as assessed by their admitting neurosurgery team

    Exclusion Criteria:
    • For the control group only, patients who have experienced a TBI in the last 6 months.

    • Diagnosis of platelet diseases or disorders, such as thrombocytopenia, thrombocytosis, or Von Willebrand disease.

    • Platelet transfusion within the last six months.

    • Comorbid regimen of Metformin within the last 6 months.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Kentucky Medical Center Lexington Kentucky United States 40536

    Sponsors and Collaborators

    • Kevin Hatton

    Investigators

    • Principal Investigator: kevin Hatton, MD, University of Kentucky

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kevin Hatton, Professor, University of Kentucky
    ClinicalTrials.gov Identifier:
    NCT04271059
    Other Study ID Numbers:
    • 54012
    First Posted:
    Feb 17, 2020
    Last Update Posted:
    Oct 28, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Kevin Hatton, Professor, University of Kentucky
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 28, 2021